ArticleGut2023
Y
Abstract readLetterComment
In one paragraph
Article in Gut, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.The oncologist · 2024Trial
- Sequential transarterial radioembolization and atezolizumab plus bevacizumab improves survival in advanced hepatocellular carcinoma.European radiology · 2026Article
- Combining Selective Internal Radiation Therapy (SIRT) and Systemic Therapy in Intrahepatic Cholangiocarcinoma.Cancers · 2026Article
- Evolving trends in yttrium-90 radioembolization research: a comprehensive bibliometric study.Annals of nuclear medicine · 2026Article
- Knowledge mapping of ⁹⁰Y transarterial radioembolization combined with immunotherapy in hepatocellular carcinoma: a bibliometric analysis.Discover oncology · 2026Article
- Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy.Liver research (Beijing, China) · 2026Review
- Yttrium-90 radioembolization as an in vivo immune modulator: clinical evidence and pharmacologic implications.Frontiers in pharmacology · 2026Article
- Post-TARE Survival Outcomes in Hepatocellular Carcinoma: Influence of Pre-TARE Immunotherapy and Targeted Therapy in a Real-World Cohort.Journal of hepatocellular carcinoma · 2026Article
- SIRT Combined with Targeted Therapy and Immunotherapy Achieves Sustained Complete Remission in Advanced Hepatocellular Carcinoma: A Case Report.Journal of hepatocellular carcinoma · 2026Article
- SIRT or TACE in combination with Lenvatinib and PD-(L)1 inhibitor in high tumor burden hepatocellular carcinoma: a multicenter, retrospective, propensity score-matched study.International journal of surgery (London, England) · 2025Article
- Article
- Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy.Cancer research communications · 2024Article
- The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications.British journal of cancer · 2024Review
- Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study.Liver cancer · 2024Article
- Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions.Seminars in interventional radiology · 2023Review
- Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.Journal of interventional medicine · 2023Article
- Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma.Cancers · 2023Review
- Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma.Journal for immunotherapy of cancer · 2023Article
Corrections and comments
- Comment on
Authors and funding
9 authors.
Licia RivoltiniUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy licia.rivoltini@istitutotumori.mi.it vincenzo.mazzaferro@istitutotumori.mi.it chiara.camisaschi@istitutotumori.mi.it.ORCID 0000-0002-2409-6225
Sherrie BhooriHPB Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Chiara CamisaschiUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy licia.rivoltini@istitutotumori.mi.it vincenzo.mazzaferro@istitutotumori.mi.it chiara.camisaschi@istitutotumori.mi.it.
Laura BergamaschiUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Luca LalliUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Paola FratiUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Davide CitterioHPB Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Chiara CastelliUnit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Vincenzo MazzaferroHPB Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy licia.rivoltini@istitutotumori.mi.it vincenzo.mazzaferro@istitutotumori.mi.it chiara.camisaschi@istitutotumori.mi.it.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsHumansImmunotherapyHEPATOCELLULAR CARCINOMAIMMUNE RESPONSEIMMUNOTHERAPYINTERVENTIONAL RADIOLOGY
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.